Loading
A phase 2 trial of Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Lantern Pharma Inc., now recruiting.
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma is a phase 2 interventional study registered as NCT05456256 by Lantern Pharma Inc., with 90 participants planned, started 2023-03-01 and due to reach its primary completion in 2026-12. Interventions recorded: LP-300, Pemetrexed and Carboplatin.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Pemetrexed, Carboplatin, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.